Targeted inhibition of miR-221/222 has been demonstrated to induce cancer cell sensitivity to TRAIL, gefitinib and erlotinib (Garofalo et al., 2009, 2011; Jang et al., 2016). Here, TNFSF10 is linked to cancer.